AMRX amneal.com: Company Value to Revenue Ratio

Amneal Pharmaceuticals, Inc. (AMRX) - corporate logo

The company's price-to-sales ratio reflects the market consensus, where 3339.88 serves as the final level marker. Amneal Pharmaceuticals (AMRX) relies on a warehouse network and strict quality control to drive supply efficiency. The business is shifting its focus toward high-cost biosimilars and injectables, reducing the share of simple tablets. A stable economic moat is maintained through US-based production and compliance with rigorous industry standards.

Amneal Pharmaceuticals Inc (AMRX): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Amneal Pharmaceuticals Inc (AMRX)

- market value and analyst target forecast:
- cash and cash flow indicators:
Initial company analysis:Amneal Pharmaceuticals
Flagship merchandise of Amneal Pharmaceuticals, Inc.

Risks of substance shortages from Asia and logistics disruptions at Amneal Pharmaceuticals (AMRX) directly impact revenue volumes, making the EV/Sales calculation critical for assessing business value regardless of debt load. This ratio compares the total enterprise value to its sales, allowing the historical EV/Sales trend to determine whether the current discount results from undervaluation or a systemic decline of the asset.

Competitor analysis for Amneal Pharmaceuticals

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple PRGO|Enterprise Value-to-Revenue Coefficient ALVO|EV/Sales Multiple LQDA (Liquidia Technologies)|EV/Sales Multiple Galapagos GLPG|ANI Pharmaceuticals Inc - EV/Sales Multiple|MNKD (MannKind Corp.) - Company Value to Revenue Ratio|AMPH: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio